Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Myoglobin for Detection of High-Risk Patients with Acute Myocarditis.

Kottwitz J, Bruno KA, Berg J, Salomon GR, Fairweather D, Elhassan M, Baltensperger N, Kissel CK, Lovrinovic M, Baltensweiler A, Schmied C, Templin C, Lima JAC, Landmesser U, Lüscher TF, Manka R, Heidecker B.

J Cardiovasc Transl Res. 2020 Jan 31. doi: 10.1007/s12265-020-09957-8. [Epub ahead of print]

PMID:
32006209
2.

Patient perception of physician empathy in stroke telemedicine.

Cheshire WP, Barrett KM, Eidelman BH, Mauricio EA, Huang JF, Freeman WD, Robinson MT, Salomon GR, Ball CT, Gamble DM, Melton VS, Meschia JF.

J Telemed Telecare. 2020 Jan 27:1357633X19899237. doi: 10.1177/1357633X19899237. [Epub ahead of print] No abstract available.

PMID:
31986965
3.

Time-resolved observation of spin-charge deconfinement in fermionic Hubbard chains.

Vijayan J, Sompet P, Salomon G, Koepsell J, Hirthe S, Bohrdt A, Grusdt F, Bloch I, Gross C.

Science. 2020 Jan 10;367(6474):186-189. doi: 10.1126/science.aay2354.

PMID:
31919220
4.

[The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].

Hechler V, Rink M, Beyersdorff D, Beer M, Beer AJ, Panebianco V, Pecoraro M, Bolenz C, Salomon G.

Urologe A. 2019 Dec;58(12):1443-1450. doi: 10.1007/s00120-019-01061-3. Review. German.

PMID:
31741002
5.

Current European Trends in Endoscopic Imaging and Transurethral Resection of Bladder Tumors.

Waldbillig F, Hein S, Grüne B, Suarez-Ibarrola R, Liatsikos E, Salomon G, Reiterer A, Gratzke C, Miernik A, Kriegmair MC, Ritter M.

J Endourol. 2019 Nov 19. doi: 10.1089/end.2019.0651. [Epub ahead of print]

PMID:
31617417
6.

Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics.

Wildeboer RR, Mannaerts CK, van Sloun RJG, Budäus L, Tilki D, Wijkstra H, Salomon G, Mischi M.

Eur Radiol. 2020 Feb;30(2):806-815. doi: 10.1007/s00330-019-06436-w. Epub 2019 Oct 10.

7.

Reply by Authors.

Mannaerts CK, Wildeboer RR, Remmers S, van Kollenburg RAA, Kajtazovic A, Hagemann J, Postema AW, van Sloun RJG, J Roobol M, Tilki D, Mischi M, Wijkstra H, Salomon G.

J Urol. 2019 Dec;202(6):1172-1173. doi: 10.1097/01.JU.0000581796.73447.de. Epub 2019 Aug 30. No abstract available.

PMID:
31469607
8.

Imaging magnetic polarons in the doped Fermi-Hubbard model.

Koepsell J, Vijayan J, Sompet P, Grusdt F, Hilker TA, Demler E, Salomon G, Bloch I, Gross C.

Nature. 2019 Aug;572(7769):358-362. doi: 10.1038/s41586-019-1463-1. Epub 2019 Aug 14.

PMID:
31413377
9.

Multiparametric Ultrasound for Prostate Cancer Detection and Localization: Correlation of B-mode, Shear Wave Elastography and Contrast Enhanced Ultrasound with Radical Prostatectomy Specimens.

Mannaerts CK, Wildeboer RR, Remmers S, van Kollenburg RAA, Kajtazovic A, Hagemann J, Postema AW, van Sloun RJG, J Roobol M, Tilki D, Mischi M, Wijkstra H, Salomon G.

J Urol. 2019 Dec;202(6):1166-1173. doi: 10.1097/JU.0000000000000415. Epub 2019 Jun 27.

PMID:
31246546
10.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T.

Eur Urol Focus. 2019 Jun 6. pii: S2405-4569(19)30145-2. doi: 10.1016/j.euf.2019.05.008. [Epub ahead of print]

PMID:
31178293
11.

[PSA increase after definitive treatment].

Maurer T, Hadaschik B, Budäus L, Steuber T, Salomon G, Horn T, Herrmann K, Weber M, Giesel FL, Berliner C, Eiber M.

Urologe A. 2019 May;58(5):569-582. doi: 10.1007/s00120-019-0931-4. German.

PMID:
31049635
12.

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.

PMID:
31047783
13.

Deep Learning for Real-time, Automatic, and Scanner-adapted Prostate (Zone) Segmentation of Transrectal Ultrasound, for Example, Magnetic Resonance Imaging-transrectal Ultrasound Fusion Prostate Biopsy.

van Sloun RJG, Wildeboer RR, Mannaerts CK, Postema AW, Gayet M, Beerlage HP, Salomon G, Wijkstra H, Mischi M.

Eur Urol Focus. 2019 Apr 23. pii: S2405-4569(19)30125-7. doi: 10.1016/j.euf.2019.04.009. [Epub ahead of print]

PMID:
31028016
14.

The Rising Star for Early Recurrent Cancer is Modern Imaging. But is it a Real Game Changer?

Salomon G.

Eur Urol Oncol. 2019 Feb;2(1):77-78. doi: 10.1016/j.euo.2018.12.009. Epub 2019 Jan 11. No abstract available.

PMID:
30929847
15.

A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.

Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, Michl U, Steuber T, Budäus L, Maurer T, Tennstedt P, Huland H, Graefen M.

BJU Int. 2019 Jun;123(6):1031-1040. doi: 10.1111/bju.14760. Epub 2019 Apr 12.

PMID:
30927303
16.

[Imaging for initial diagnosis of localized prostate cancer].

Bonekamp D, Salomon G.

Urologe A. 2019 May;58(5):494-503. doi: 10.1007/s00120-019-0901-x. Review. German.

PMID:
30874832
17.

Impact of the estimated blood loss during radical prostatectomy on functional outcomes.

Preisser F, Pompe RS, Salomon G, Rosenbaum C, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Urol Oncol. 2019 May;37(5):298.e11-298.e17. doi: 10.1016/j.urolonc.2019.01.006. Epub 2019 Mar 8.

PMID:
30857988
18.

Future of focal therapy for the treatment of prostate cancer- european section of urotechnology (ESUT) position.

Barret E, Ganzer R, Salomon G, Fielder M, Celia A, Enikeev D, Martínez-Salamanca JI, Liatsikos E, Gómez Rivas J.

Arch Esp Urol. 2019 Mar;72(2):167-173. Review.

PMID:
30855018
19.

Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.

Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D.

Eur Urol. 2019 Jul;76(1):106-114. doi: 10.1016/j.eururo.2019.01.048. Epub 2019 Feb 14.

PMID:
30772034
20.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment.

Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H.

World J Urol. 2019 Dec;37(12):2657-2662. doi: 10.1007/s00345-019-02668-z. Epub 2019 Feb 6.

PMID:
30725166
21.

Author Correction: Direct observation of incommensurate magnetism in Hubbard chains.

Salomon G, Koepsell J, Vijayan J, Hilker TA, Nespolo J, Pollet L, Bloch I, Gross C.

Nature. 2019 Feb;566(7743):E5. doi: 10.1038/s41586-019-0906-z.

PMID:
30670874
22.

Direct observation of incommensurate magnetism in Hubbard chains.

Salomon G, Koepsell J, Vijayan J, Hilker TA, Nespolo J, Pollet L, Bloch I, Gross C.

Nature. 2019 Jan;565(7737):56-60. doi: 10.1038/s41586-018-0778-7. Epub 2018 Dec 12. Erratum in: Nature. 2019 Feb;566(7743):E5.

PMID:
30542155
23.

[Partial gland ablation with vascular-targeted phototherapy versus active surveillance for low-risk prostate cancer : Results of a randomized trial].

Salomon G.

Urologe A. 2018 Dec;57(12):1496-1498. doi: 10.1007/s00120-018-0809-x. German. No abstract available.

PMID:
30446781
24.

Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes.

Pompe RS, Leyh-Bannurah SR, Preisser F, Salomon G, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Urol Oncol. 2018 Dec;36(12):527.e21-527.e28. doi: 10.1016/j.urolonc.2018.08.010. Epub 2018 Nov 12.

PMID:
30442538
25.

Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens.

Mannaerts CK, Wildeboer RR, Postema AW, Hagemann J, Budäus L, Tilki D, Mischi M, Wijkstra H, Salomon G.

BMC Urol. 2018 Nov 8;18(1):98. doi: 10.1186/s12894-018-0409-5.

26.

Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.

Pierrard V, Lebdai S, Kleinclauss F, Azzouzi AR, Terrier JE, Fortier E, Joniau S, Van Der Poel H, Salomon G, Casanova J, Medina-Lopez RA, Potiron E, Rigaud J, Vincendeau S, Rassweiler J, Villers A, Gaston R, Saussine C, Giai J, Gaillac B, Emberton M, Ruffion A.

J Urol. 2019 Feb;201(2):315-321. doi: 10.1016/j.juro.2018.08.084.

PMID:
30248343
27.

Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates.

Salomon G, Prues S, Saul J, Budäus L, Tilki D, Schneider M, Haferkamp A, Graefen M, Boehm K.

Eur Urol Focus. 2019 Nov;5(6):992-997. doi: 10.1016/j.euf.2018.06.005. Epub 2018 Jun 23.

PMID:
29941389
28.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
29.

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF.

Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10. Review.

30.

Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement.

Ganzer R, Arthanareeswaran VKA, Ahmed HU, Cestari A, Rischmann P, Salomon G, Teber D, Liatsikos E, Stolzenburg JU, Barret E.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):175-186. doi: 10.1038/s41391-018-0042-0. Epub 2018 May 9. Review.

31.

Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients.

Schiffmann J, Karakiewicz PI, Rink M, Manka L, Salomon G, Tilki D, Budäus L, Pompe R, Leyh-Bannurah SR, Haese A, Hammerer P, Huland H, Graefen M, Tennstedt P.

World J Urol. 2018 Jul;36(7):1067-1072. doi: 10.1007/s00345-018-2240-8. Epub 2018 Mar 2.

PMID:
29497861
32.

Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Pompe RS, Kühn-Thomä B, Nagaraj Y, Veleva V, Preisser F, Leyh-Bannurah SR, Graefen M, Huland H, Tilki D, Salomon G.

World J Urol. 2018 May;36(5):705-712. doi: 10.1007/s00345-018-2238-2. Epub 2018 Feb 28.

PMID:
29492583
33.

Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram.

Pompe RS, Bandini M, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, Shariat SF, Karakiewicz PI.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):386-393. doi: 10.1038/s41391-018-0033-1. Epub 2018 Feb 27.

PMID:
29487397
34.

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial.

Salomon G, Saul J, Prues S, Schneider M, Budäus L, Tilki D, Rohde H, Haferkamp A, Graefen M, Boehm K.

World J Urol. 2018 Jun;36(6):871-876. doi: 10.1007/s00345-018-2221-y. Epub 2018 Feb 7.

PMID:
29417288
35.

Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy.

Kratzenberg J, Salomon G, Tennstedt P, Dell'Oglio P, Tilki D, Haferkamp A, Graefen M, Boehm K.

World J Urol. 2018 Apr;36(4):623-628. doi: 10.1007/s00345-018-2178-x. Epub 2018 Jan 13.

PMID:
29332260
36.

Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy.

Sauer M, Weinrich JM, Fraune C, Salomon G, Tennstedt P, Adam G, Beyersdorff D.

Eur J Radiol. 2018 Jan;98:187-192. doi: 10.1016/j.ejrad.2017.11.019. Epub 2017 Nov 27.

PMID:
29279161
37.

Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.

Salomon G, Maza A, Boulinguez S, Paul C, Lamant L, Tournier E, Mazereeuw-Hautier J, Meyer N.

Br J Dermatol. 2018 May;178(5):1199-1203. doi: 10.1111/bjd.16270. Epub 2018 Feb 26.

PMID:
29274233
38.

Effect of repeat prostate biopsies on functional outcomes after radical prostatectomy.

Rosenbaum CM, Mandel P, Tennstedt P, Preisser F, Marks P, Chun FK, Graefen M, Tilki D, Salomon G.

Urol Oncol. 2018 Mar;36(3):91.e17-91.e22. doi: 10.1016/j.urolonc.2017.11.016. Epub 2017 Dec 13.

PMID:
29246393
39.

[Focal therapy of prostate cancer].

Ganzer R, Franiel T, Köllermann J, Kuru T, Baumunk D, Blana A, Hadaschik B, von Hardenberg J, Henkel T, Köhrmann KU, Liehr UB, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Wendler J, Witzsch U, Schostak M.

Urologe A. 2017 Oct;56(10):1335-1346. doi: 10.1007/s00120-017-0488-z. German.

PMID:
28856386
40.

Differences in Recurrence Rate and De Novo Incontinence after Endoscopic Treatment of Vesicourethral Stenosis and Bladder Neck Stenosis.

Kranz J, Reiss PC, Salomon G, Steffens J, Fisch M, Rosenbaum CM.

Front Surg. 2017 Aug 10;4:44. doi: 10.3389/fsurg.2017.00044. eCollection 2017.

41.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N.

Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.

42.

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Mandel P, Rosenbaum C, Pompe RS, Steuber T, Salomon G, Chun FK, Graefen M, Huland H, Tilki D.

World J Urol. 2017 Dec;35(12):1833-1839. doi: 10.1007/s00345-017-2079-4. Epub 2017 Aug 21.

PMID:
28828530
43.

Revealing hidden antiferromagnetic correlations in doped Hubbard chains via string correlators.

Hilker TA, Salomon G, Grusdt F, Omran A, Boll M, Demler E, Bloch I, Gross C.

Science. 2017 Aug 4;357(6350):484-487. doi: 10.1126/science.aam8990.

PMID:
28774925
44.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P.

Eur Urol Focus. 2017 Dec;3(6):646-649. doi: 10.1016/j.euf.2017.06.016. Epub 2017 Jul 8.

PMID:
28753877
45.

Esterase Profile in Drosophila mercatorum pararepleta (Diptera; Drosophilidae), a Non-cactophilic Species of the repleta Group: Development Patterns and Aspects of Genetic Variability.

de Barros Machado LP, Alves NS, de Oliveira Prestes J, Salomón GR, Biegai D, Wouk T, Mateus RP.

Zool Stud. 2017 Jul 25;56:e21. doi: 10.6620/ZS.2017.56-21. eCollection 2017.

46.

Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.

Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, Salomon G, Graefen M, Huland H, Tilki D.

J Urol. 2017 Aug;198(2):354-361. doi: 10.1016/j.juro.2017.02.070. Epub 2017 Feb 16.

PMID:
28216329
47.

Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.

Schiffmann J, Salomon G, Tilki D, Budäus L, Karakiewicz PI, Leyh-Bannurah SR, Pompe RS, Haese A, Heinzer H, Huland H, Graefen M, Tennstedt P.

Urol Oncol. 2017 May;35(5):243-249. doi: 10.1016/j.urolonc.2016.12.014. Epub 2017 Feb 1.

PMID:
28161322
48.

High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.

Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis MC, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E286. doi: 10.3390/ijms18020286.

49.

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2017 Jan 10;8(2):3761. doi: 10.18632/oncotarget.14557. No abstract available.

50.

Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AAA, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T.

Eur Urol. 2018 May;73(5):674-683. doi: 10.1016/j.eururo.2017.01.015. Epub 2017 Jan 20.

PMID:
28117112

Supplemental Content

Loading ...
Support Center